Replimune Group, Inc. cotiza a 13.07 USD y tiene una capitalización bursátil de $1.2B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune …
| Periodo | 2026-11 | 2026-08 | 2026-08 | 2026-06 |
|---|---|---|---|---|
| Real | — | $-0.72 | — | $-0.76 |
| Estimado | $-0.79 | $-0.77 | $-0.77 | $-0.72 |
| Sorpresa | — | +6.5% | — | -5.6% |
| Métrica | REPL | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -188.9% | -40.4% | -148.5% |
| ROA | -94.5% | -32.0% | -62.4% |
| Current Ratio | 4.79 | 2.84 | +1.95 |
| Debt / Equity | 0.50 | 0.28 | +0.22 |